Literature DB >> 22526022

Neuromyelitis optica IgG and natural killer cells produce NMO lesions in mice without myelin loss.

Julien Ratelade1, Hua Zhang, Samira Saadoun, Jeffrey L Bennett, Marios C Papadopoulos, A S Verkman.   

Abstract

The pathogenesis of neuromyelitis optica (NMO) involves targeting of NMO-immunoglobulin G (NMO-IgG) to aquaporin-4 (AQP4) on astrocytes in the central nervous system. Prior work provided evidence for complement-dependent cytotoxicity (CDC) in NMO lesion development. Here, we show that antibody-dependent cellular cytotoxicity (ADCC), in the absence of complement, can also produce NMO-like lesions. Antibody-dependent cellular cytotoxicity was produced in vitro by incubation of mouse astrocyte cultures with human recombinant monoclonal NMO-IgG and human natural killer cells (NK-cells). Injection of NMO-IgG and NK-cells in mouse brain caused loss of AQP4 and GFAP, two characteristic features of NMO lesions, but little myelin loss. Lesions were minimal or absent following injection of: (1) control (non-NMO) IgG with NK-cells; (2) NMO-IgG and NK-cells in AQP4-deficient mice; or (3) NMO-IgG and NK-cells in wild-type mice together with an excess of mutated NMO-IgG lacking ADCC effector function. NK-cells greatly exacerbated NMO lesions produced by NMO-IgG and complement in an ex vivo spinal cord slice model of NMO, causing marked myelin loss. NMO-IgG can thus produce astrocyte injury by ADCC in a complement-independent and dependent manner, suggesting the potential involvement of ADCC in NMO pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22526022      PMCID: PMC3581313          DOI: 10.1007/s00401-012-0986-4

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  48 in total

1.  Elevated NK-mediated lysis of Raji and Daudi cells carrying fixed iC3b fragments.

Authors:  O F Ramos; B Nilsson; K Nilsson; G Eggertsen; E Yefenof; E Klein
Journal:  Cell Immunol       Date:  1989-04-01       Impact factor: 4.868

2.  Differential expression of individual complement regulators in the brain and choroid plexus.

Authors:  S K Singhrao; J W Neal; N K Rushmere; B P Morgan; P Gasque
Journal:  Lab Invest       Date:  1999-10       Impact factor: 5.662

Review 3.  The biology of natural killer cells and implications for therapy of human disease.

Authors:  E G Chiorean; J S Miller
Journal:  J Hematother Stem Cell Res       Date:  2001-08

4.  SHP-1- and phosphotyrosine-independent inhibitory signaling by a killer cell Ig-like receptor cytoplasmic domain in human NK cells.

Authors:  Sei-ichi Yusa; Tracey L Catina; Kerry S Campbell
Journal:  J Immunol       Date:  2002-05-15       Impact factor: 5.422

5.  Effects of IFN on human eosinophils in comparison with other cytokines. A novel class of eosinophil activators with delayed onset of action.

Authors:  T Valerius; R Repp; J R Kalden; E Platzer
Journal:  J Immunol       Date:  1990-11-01       Impact factor: 5.422

6.  Fc receptors for IgG on cultured human microglia mediate cytotoxicity and phagocytosis of antibody-coated targets.

Authors:  E Ulvestad; K Williams; R Matre; H Nyland; A Olivier; J Antel
Journal:  J Neuropathol Exp Neurol       Date:  1994-01       Impact factor: 3.685

7.  Expression of decay-accelerating factor (CD55), membrane cofactor protein (CD46) and CD59 in the human astroglioma cell line, D54-MG, and primary rat astrocytes.

Authors:  C Yang; J L Jones; S R Barnum
Journal:  J Neuroimmunol       Date:  1993-09       Impact factor: 3.478

8.  A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica.

Authors:  Claudia F Lucchinetti; Raul N Mandler; Dorian McGavern; Wolfgang Bruck; Gerald Gleich; Richard M Ransohoff; Corinna Trebst; Brian Weinshenker; Dean Wingerchuk; Joseph E Parisi; Hans Lassmann
Journal:  Brain       Date:  2002-07       Impact factor: 13.501

9.  Binding of monomeric human IgG defines an expression polymorphism of Fc gamma RIII on large granular lymphocyte/natural killer cells.

Authors:  B A Vance; T W Huizinga; K Wardwell; P M Guyre
Journal:  J Immunol       Date:  1993-12-01       Impact factor: 5.422

10.  IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel.

Authors:  Vanda A Lennon; Thomas J Kryzer; Sean J Pittock; A S Verkman; Shannon R Hinson
Journal:  J Exp Med       Date:  2005-08-08       Impact factor: 14.307

View more
  51 in total

Review 1.  Aquaporin 4 and neuromyelitis optica.

Authors:  Marios C Papadopoulos; A S Verkman
Journal:  Lancet Neurol       Date:  2012-05-16       Impact factor: 44.182

2.  Involvement of antibody-dependent cell-mediated cytotoxicity in inflammatory demyelination in a mouse model of neuromyelitis optica.

Authors:  Julien Ratelade; Nithi Asavapanumas; Alanna M Ritchie; Scott Wemlinger; Jeffrey L Bennett; A S Verkman
Journal:  Acta Neuropathol       Date:  2013-08-31       Impact factor: 17.088

3.  Determining the Spatial Relationship of Membrane-Bound Aquaporin-4 Autoantibodies by STED Nanoscopy.

Authors:  John N Soltys; Stephanie A Meyer; Hannah Schumann; Emily A Gibson; Diego Restrepo; Jeffrey L Bennett
Journal:  Biophys J       Date:  2017-04-25       Impact factor: 4.033

4.  Optic neuritis in neuromyelitis optica.

Authors:  Marc H Levin; Jeffrey L Bennett; A S Verkman
Journal:  Prog Retin Eye Res       Date:  2013-03-30       Impact factor: 21.198

5.  Human immunoglobulin G reduces the pathogenicity of aquaporin-4 autoantibodies in neuromyelitis optica.

Authors:  Julien Ratelade; Alex J Smith; A S Verkman
Journal:  Exp Neurol       Date:  2014-03-14       Impact factor: 5.330

Review 6.  Biology of AQP4 and anti-AQP4 antibody: therapeutic implications for NMO.

Authors:  A S Verkman; Puay-Wah Phuan; Nithi Asavapanumas; Lukmanee Tradtrantip
Journal:  Brain Pathol       Date:  2013-11       Impact factor: 6.508

Review 7.  Treatment of neuromyelitis optica: state-of-the-art and emerging therapies.

Authors:  Marios C Papadopoulos; Jeffrey L Bennett; Alan S Verkman
Journal:  Nat Rev Neurol       Date:  2014-08-12       Impact factor: 42.937

8.  Enzymatic deglycosylation converts pathogenic neuromyelitis optica anti-aquaporin-4 immunoglobulin G into therapeutic antibody.

Authors:  Lukmanee Tradtrantip; Julien Ratelade; Hua Zhang; A S Verkman
Journal:  Ann Neurol       Date:  2012-10-10       Impact factor: 10.422

9.  Early loss of oligodendrocytes in human and experimental neuromyelitis optica lesions.

Authors:  Claudia Wrzos; Anne Winkler; Imke Metz; Dieter M Kayser; Dietmar R Thal; Christiane Wegner; Wolfgang Brück; Stefan Nessler; Jeffrey L Bennett; Christine Stadelmann
Journal:  Acta Neuropathol       Date:  2013-11-30       Impact factor: 17.088

10.  Unique neuromyelitis optica pathology produced in naïve rats by intracerebral administration of NMO-IgG.

Authors:  Nithi Asavapanumas; Julien Ratelade; A S Verkman
Journal:  Acta Neuropathol       Date:  2013-11-05       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.